Promising Pediatric Data for Albireo’s A4250 to be Presented at The International Liver Congress™ 2017

Data supports advancement of A4250 into a planned Phase 3 trial in patients with progressive familial intrahepatic cholestasis Pruritus improvement and reduction in serum bile acid levels in most patients in Phase 2 clinical trial in children with cholestatic liver disease. BOSTON, April 22, 2017 (GLOBE NEWSWIRE) — Albireo Pharma, Inc.